<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191044</url>
  </required_header>
  <id_info>
    <org_study_id>THESIS</org_study_id>
    <nct_id>NCT04191044</nct_id>
  </id_info>
  <brief_title>Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)</brief_title>
  <acronym>THESIS</acronym>
  <official_title>Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Marqués de Valdecilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease
      in our environment. Preliminary data suggest that portal hypertension may exist in the
      initial phases of NAFLD due to mechanisms that have not yet been elucidated. The clinical
      relevance of its development in these initial phases is unknown, while in more advanced
      phases new data are required to confirm the close relationship between portal hypertension
      and the risk of decompensation described in other etiologies. Likewise, the influence of
      fibrosis and portal hypertension on the cardiovascular risk of patients with NAFLD is
      unknown. The aim of the present multicenter project is to characterize the presence of portal
      hypertension and the mechanisms involved in its development in the different stages of NAFLD,
      to assess the association between the degree of portal hypertension and the development of
      portal hypertension-related complications, to know the early cardiovascular risk in the
      different stages of the disease, and to identify noninvasive biomarkers of the presence and
      severity of portal hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with NAFLD without advanced fibrosis and severe steatosis with portal hypertension</measure>
    <time_frame>1 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with NAFLD and advanced fibrosis with portal hypertension</measure>
    <time_frame>1 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of the mechanisms responsible for the appearance of portal hypertension by specifically assessing the following</measure>
    <time_frame>1 months</time_frame>
    <description>An increase in sinusoidal vascular resistance and the relative importance of its structural (sinusoidal compression) and functional (endothelial dysfunction and activation of starry cells) components, Splanchnic vasodilatation leading to portal hyperflow and hyperdynamic circulation, proinflammatory state and Activation of angiogenesis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Threshold of portal hypertension leading to portal hypertension-related complications in patients with NAFLD</measure>
    <time_frame>1months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of portal hypertension and hepatic fibrosis on early cardiovascular risk and the degree of liver and kidney function.</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive biomarkers of the presence and severity of portal hypertension through metabolomics, extracellular vesicles and / or other analytical markers</measure>
    <time_frame>1 months</time_frame>
    <description>liquid biopsy</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>NAFLD with mild steatosis and grade &lt;3 fibrosis in patients</arm_group_label>
    <description>NAFLD with mild steatosis and grade &lt;3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index&gt; 2.6) or diabetes mellitus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD with severe steatosis and grade &lt;3 fibrosis in patients</arm_group_label>
    <description>NAFLD with severe steatosis and grade &lt;3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index&gt; 2.6) or diabetes mellitus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD with advanced fibrosis</arm_group_label>
    <description>NAFLD with advanced fibrosis (i.e. grade 3 or 4 fibrosis) without previous portal hypertension-related complications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decompensated NAFLD cirrhosis</arm_group_label>
    <description>Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage, and/or hepatic encephalopathy) up to Child B (9 points)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>A complete cardiovascular and liver characterization will be carried out</intervention_name>
    <description>A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.</description>
    <arm_group_label>Decompensated NAFLD cirrhosis</arm_group_label>
    <arm_group_label>NAFLD with advanced fibrosis</arm_group_label>
    <arm_group_label>NAFLD with mild steatosis and grade &lt;3 fibrosis in patients</arm_group_label>
    <arm_group_label>NAFLD with severe steatosis and grade &lt;3 fibrosis in patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be used to measure inflammation markers and other laboratory parameters.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non-alcoholic fatty liver disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 65 years.

          -  Clinical suspicion of NAFLD.

          -  Severe (controlled attenuation parameter (CAP) ≥330 dB/m) or mild steatosis (CAP:
             298-317 dB / m), and FibroScan® grade 2 fibrosis (M probe: 7-9 kpa; XL probe: 5-7.5
             kpa) in patients with grade 1 or 2 obesity and insulin resistance (HOMA index&gt; 2.6) or
             diabetes mellitus.

          -  Fibroscan® grade 3 or 4 fibrosis (M probe:&gt; 9 kpa; XL probe:&gt; 7.5 kpa).

          -  Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage,
             and/or hepatic encephalopathy) up to Child B (9 points).

          -  Signature of informed consent.

        Exclusion Criteria:

          -  Concomitant liver disease and patients with acute on chronic liver failure.

          -  Excessive alcohol consumption (≥ 30 grams per day in men and ≥ 20 grams per day in
             women).

          -  Comorbidities (HIV infection, connective diseases, prothrombotic disorders) and/or
             drugs (didanosine, azathioprine, oxaliplatin) associated with the presence of
             idiopathic non-cirrhotic portal hypertension.

          -  Clinical history of cardiovascular disease (ischemic cardiomyopathy, atrial
             fibrillation, valvular defects, severe arterial hypertension, previous
             hospitalizations secondary to heart failure, cerebrovascular disease).

          -  Severe renal impairment, defined by creatinine clearance &lt;15 ml/min/1.73m2.

          -  Any previous or current thrombosis in any venous territory.

          -  Uncontrolled psychiatric illness

          -  Contraindication to liver biopsy or any of the complementary tests included in the
             project.

          -  Hepatocellular carcinoma that does not meet Milan criteria.

          -  Pregnancy or breastfeeding

          -  Significant comorbidities that entail a functional limitation and/or a life expectancy
             of less than 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Ignacio Fortea</last_name>
    <phone>+34 942 204084</phone>
    <email>jifortea@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucia Lavin Alconero</last_name>
    <phone>+34 942 204084</phone>
    <email>eclinicos5@idival.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Baffy G. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2018 Mar;63(3):563-576. doi: 10.1007/s10620-017-4903-5. Epub 2018 Jan 22. Review.</citation>
    <PMID>29368124</PMID>
  </reference>
  <reference>
    <citation>Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Van Gaal L, Michielsen P. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1449-57. doi: 10.1097/MEG.0b013e32833f14a1.</citation>
    <PMID>21389796</PMID>
  </reference>
  <reference>
    <citation>Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012 Sep;10(9):1028-33.e2. doi: 10.1016/j.cgh.2012.05.008. Epub 2012 May 18.</citation>
    <PMID>22610002</PMID>
  </reference>
  <reference>
    <citation>Rodrigues SG, Montani M, Guixé-Muntet S, De Gottardi A, Berzigotti A, Bosch J. Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2101-2109.e1. doi: 10.1016/j.cgh.2018.12.038. Epub 2019 Jan 6.</citation>
    <PMID>30625404</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-alcoholic fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

